{"id":390038,"date":"2021-04-27T00:00:00","date_gmt":"2021-04-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0023-2021-biopharma-multiple-sclerosis-access-and-reimbursement-us-2021\/"},"modified":"2026-03-31T10:43:27","modified_gmt":"2026-03-31T10:43:27","slug":"acrecg0023-2021-biopharma-multiple-sclerosis-access-and-reimbursement-us-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0023-2021-biopharma-multiple-sclerosis-access-and-reimbursement-us-2021\/","title":{"rendered":"Multiple Sclerosis | Access and Reimbursement | US | 2021"},"content":{"rendered":"<p>The multiple sclerosis (MS) therapy market continues to evolve with each new FDA-approved disease-modifying therapy (DMT) further expanding treatment choice. The newest entrants (e.g., Kesimpta, Vumerity, Zeposia) and nearest-to-launch emerging therapies (e.g., Ponvory, ublituximab, GA Depot) are entering established drug classes, and although many offer a unique advantage over first-in-class options, they may struggle unless developers demonstrate meaningful differentiation for payers and prescribers. Meanwhile, the recent debut of generics competition for former market-leader Tecfidera\u2014and the anticipated launch of several other oral generics in the coming years\u2014will exert a new pressure on formulary placement and physician choice, especially in the relapsing MS space. For developers bringing novel or next-generation DMTs to market, understanding the current and future influence of clinical metrics and value-for-dollar on access and prescribing will be key.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What is the current formulary status of MS DMTs, and what approaches do payers use to manage utilization and costs?<\/li>\n<li>How will MCOs assess value and formulary placement for emerging DMTs? How will new agents be prescribed in an increasingly crowded and high-cost MS market?<\/li>\n<li>How will the clinical differentiators of some next-in-class agents (e.g., Kesimpta, Zeposia, Ponvory) be viewed from a payer and physician perspective?<\/li>\n<li>How will generic competition for Tecfidera affect coverage and prescribing in the MS market?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>U.S. Access &#038; Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.<\/p>\n<p><strong>Markets covered:<\/strong><strong> <\/strong> United States<\/p>\n<p><strong>Primary research:<\/strong><\/p>\n<ul>\n<li>Survey of 100 U.S. neurologists.<\/li>\n<li>Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs\/MDs).<\/li>\n<\/ul>\n<p><strong>Key companies: <\/strong>Roche, Merck, Novartis, Receptos, Celgene, AB Science, Viatris \/ Mapi Pharma, TG Therapeutics, Janssen, Sanofi, EMD Serono<\/p>\n<p><strong>Key drugs: <\/strong>Aubagio, Bafiertam, Tecfidera \/ dimethyl fumarate, Copaxone \/ glatiramer acetate, Gilenya, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Tysabri, Vumerity, Zeposia, BTK inhibitors, GA Depot, masitinib, Ponvory, ublituximab<\/p>\n<p><strong>Content highlights:<\/strong><\/p>\n<ul>\n<li>Reimbursement and contracting.<\/li>\n<li>Access and prescribing.<\/li>\n<li>Opportunities and challenges for emerging therapies.<\/li>\n<li>Disease-specific special topics.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390038","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390038\/revisions"}],"predecessor-version":[{"id":576413,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390038\/revisions\/576413"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}